1.2 Million Invested in MS Care and Innovation
Novartis Pharmaceuticals Canada Inc. (Novartis) announced today an investment of 1.2 million in Alberta to collaborate with the Alberta government to advance care and innovation in multiple sclerosis (MS). This investment by Novartis, for MS research, marks the first collaboration under a memorandum of understanding (MOU) between Novartis and the Alberta government intended to stimulate health research and innovation in the province of Alberta.
The 1.2-million Novartis investment will support research for the treatment of MS. The goal is to look at novel innovations, evaluation methods and care pathways and to translate these into practice to further the understanding of the disease and care of MS patients.
For more details, see the FULL ARTICLE.
Press + Media
- Print Press Coverage
- TV Press Coverage
- Online Press Coverage
- Foundation Videos
- Foundation Blog
- Press Materials
Topics of Interest
Posted: Jan 20, 2015Given the fact that MS is a chronic, progressive, and disabling disease for which there is no ...
Posted: May 12, 2014Please join us for an opportunity to hear from our ...
Posted: Apr 07, 2014Please join us on May 2, 2014 at the Hyatt ...
Posted: Sep 24, 2013Taking place at the Hyatt Regency Century City on December ...